SCHF - Schwab International Equity ETF

NYSEArca - NYSEArca Delayed Price. Currency in USD
-0.19 (-0.56%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close34.19
Bid0.00 x 4000
Ask0.00 x 2200
Day's Range33.92 - 34.05
52 Week Range31.35 - 36.35
Avg. Volume2,095,424
Net Assets15.33B
PE Ratio (TTM)N/A
YTD Return0.35%
Beta (3y)0.96
Expense Ratio (net)0.06%
Inception Date2009-11-03
Trade prices are not sourced from all markets
  • Analyzing the Possible Impacts of the Iran Deal Exit
    Market Realist14 days ago

    Analyzing the Possible Impacts of the Iran Deal Exit

    President Trump’s decision to withdraw from the Joint Comprehensive Plan of Action (or JCPOA) could lead to regional conflicts in the Middle East. Israel and Saudi Arabia, two of Iran’s neighbors, have extended support to President Trump’s decision, which could escalate the tensions in the region. Stock prices of energy (XLE) companies like Marathon Oil (MRO) and Hess have zoomed higher since the Iran deal pull-out and look set for further gains if crude prices continue to surge.

  • 3 ETFs to Help You Build Retirement Wealth
    Motley Fool7 months ago

    3 ETFs to Help You Build Retirement Wealth

    These picks might surprise you, but they'll serve you well.

  • ETF.com9 months ago

    A Deeper Dive Into ESG ETF Portfolios

    The world is full of model ETF portfolios, but we’re just starting to see the environmental, socially responsible and governance (ESG) filter as a consideration on many. The biggest recent news on this front was the development by robo-platform Betterment of an ESG version of its core portfolio last month.

  • Market Realist10 months ago

    Novartis in 2Q17: Performance of Alcon

    For 2Q17, Alcon reported a 1.0% growth in revenues to $1.52 billion compared to $1.51 billion in 2Q16.

  • Benzinga10 months ago

    Rapid Growth For This International ETF

    Several of this year's top asset-gathering exchange traded funds are products focusing on developed market equities outside the U.S. Amid the rush to developed market ex-U.S. ETFs, another theme is becoming ...

  • Market Realist10 months ago

    Novartis’s 2Q17 Estimates: How Sandoz Might Perform

    Revenues for Sandoz are expected to report operational growth in 2Q17 following an increased demand for biopharmaceuticals.

  • Market Realist11 months ago

    Novartis Stock in 2Q17: How Has It Performed?

    Headquartered in Basel, Switzerland, Novartis (NVS) is a pharmaceutical company specializing in the research, development, manufacturing, and marketing of a broad range of healthcare products, mainly pharmaceuticals. ...

  • 3 Top International ETFs for 2017 and Beyond
    Motley Fool11 months ago

    3 Top International ETFs for 2017 and Beyond

    Exchange-traded funds that hold only foreign stocks can add diversification and high growth potential to your portfolio.

  • Forbes11 months ago

    The Single-Best Retirement Fund Booster

    You can make one solid move this year to boost your retirement savings. Here's what you need to know.

  • Market Realistlast year

    Inside Novartis’s Innovative Medicines Segment in 1Q17

    Novartis’s (NVS) Innovative Medicines segment contributed ~67% of NVS's total revenues in 1Q17.

  • Market Realistlast year

    GlaxoSmithKline’s Pharmaceuticals Segment in 1Q17

    The Pharmaceuticals segment reported an operational growth of 4.0% and a 13.0% positive impact of foreign exchange, resulting in a rise of 17.0% in revenues.

  • Market Realistlast year

    How AstraZeneca’s Growth Platforms Performed in 1Q17

    A few of the segments AstraZeneca identifies as growth platforms include Respiratory products, new Cardiovascular and Metabolic Diseases products, and new Oncology products.

  • Market Realistlast year

    Performance of Sanofi Genzyme in 1Q17

    Sanofi (SNY) reported growth of over 15% at constant exchange rates in its 1Q17 revenues from Genzyme.